A broad–spectrum, second-generation triazole antifungal drug called Posaconazole is efficient towards a greater variety of mostly recognized causatives like Aspergillus, Candida, Cryptococcus neoformans, Fusarium species, and Zygomycetes species, for preventive therapy of mucormycosis in today’s trends. A comparative study reveals that Posaconazole safety and efficiency in comparison with Itraconazole is higher using nine pharmacokinetic models. Posaconazole, a basic, poorly soluble, high molecular weight drug, is cyp450 dependent. It acts by inhibition of lanosterol 14-demethylase responsible for ergosterol synthesis hung on membranes of cells to prevent multiplicity and achieve its antifungal effect. A cumulative review of Posaconazole as of literature reports, analyzed by HPLC equipped with Fluorometric, DAD/ UV/ PDA, MS/MS. HPTLC, UHPLC - UV, UPLC - UV MS/MS. Stability analysis of forced degradation by P – HPLC, IR, NMR, LC-MS (ESI – QTOP). Bioanalytical samples were studied by RP – HPLC,and impurities upon degradation were also analyzed.